426PD - A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Date 10 October 2016
Event ESMO 2016 Congress
Session Endocrine and neuroendocrine tumours
Topics Anticancer Agents
Neuroendocrine Tumours
Biological Therapy
Presenter Jules Derks
Citation Annals of Oncology (2016) 27 (6): 136-148. 10.1093/annonc/mdw369
Authors J.L. Derks1, R.J. van Suylen2, E. Thunnissen3, M.A. Den Bakker4, H. Groen5, E.F. Smit6, R.A. Damhuis7, E. Speel8, A.C. Dingemans9
  • 1Department Of Resipratory Diseases, Maastricht University Medical Center (MUMC), P.O. Box 616, 6200 MD - Maastricht/NL
  • 2Pathology-dna, Jeroen Bosch Hospital, 's-Hertogenbosch/NL
  • 3Department Of Pathology, VU University Medical Center,, Amsterdam/NL
  • 4Department Of Pathology, Maasstad Hospital, Rotterdam/NL
  • 5Department Of Pulmonary Diseases, University Hospital Groningen (UMCG), Groningen/NL
  • 6Department Of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam/NL
  • 7Department Of Research, Comprehensive Cancer Association, Utrecht/NL
  • 8Department Of Pathology, Maastricht University Medical Center (MUMC), Maastricht/NL
  • 9Department Of Resipratory Diseases, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL



It is unclear what constitutes optimal chemotherapy for metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC). Expert opinion based guidelines favor platinum-etoposide, i.e. small cell lung carcinoma (SCLC) type chemotherapy treatment. However, data are lacking due to low incidence of LCNEC and changes in diagnosis after pathology revision. In a population based, pathology revised LCNEC series we compared overall survival (OS) of non-small cell lung carcinoma (NSCLC) and SCLC type chemotherapy treatment.


Data of the Dutch Pathology Registry (PALGA) and Netherlands Cancer Registry were combined and searched for patients with stage IV definite LCNEC and possible LCNEC treated with chemotherapy, diagnosed between 2003-2012. In 207 patients original tumor specimen slides were available for central revision blinded for clinical information. Data on clinical characteristics, chemotherapy and OS were retrieved. First-line platinum chemotherapy was clustered: 1) NSCLC type treatment including gemcitabine, docetaxel, paclitaxel and vinorelbine, 2) pemetrexed (Pem-NSCLC), and 3) SCLC type treatment including etoposide. Multivariate regression analysis included variables significant at univariate analysis and the variables gender and age.


128 patients had panel-consensus definite LCNEC. 62% (N = 79) received ≥4 cycles and 26% (N = 33) ≤2 cycles of chemotherapy. NSCLC type chemotherapy was administered in 46% (N = 60), Pem-NSCLC in 16% (N = 20), and SCLC type in 38% (N = 48) patients. NSCLC type chemotherapy treated patients had a median OS of 8.5 [95% confidence interval (CI) 7.0-9.9] months, significantly higher than treatment with Pem-NSCLC; median 5.9 [95% CI 5.0-6.9] months (Hazard Ratio (HR) = 2.51 [95% CI 1.39-4.52], p = 0.002) and SCLC; median 6.7 [95% CI 5.0-8.5] months (HR = 1.66 [1.08-2.56], p = 0.02).


This population based analysis on outcome of chemotherapy in patients with panel-consensus LCNEC shows that NSCLC type chemotherapy treatment leads to prolonged OS when compared to SCLC and Pem-NSCLC type chemotherapy treatment.

Clinical trial identification

Legal entity responsible for the study

Maastricht University Medical Centre


This study was supported by a grant from the Dutch Cancer Society (KWF: number 7110)


H. Groen: Other from Lilly, GSK, Merck, Pfizer, Roche, BMS, outside the submitted work; .

E-J. Speel: Other from Pfizer, other from Roche, other from Amgen, outside the submitted work; .

A-M.C. Dingemans: Personal fees from Roche, BMS, Boehringer Ingelheim, Astra Zeneca, Eli Lilly, MSD, Pfizer, and Amgen, outside the submitted work;.

All other authors have declared no conflicts of interest.